Back

A Mixed Probiotic/Prebiotic Intervention (MBR 01) for the Management of Diarrhea During Abemaciclib Treatment of Early Breast Cancer: A Single Center Prospective Case Control Pilot Study

2026-02-17 oncology Title + abstract only
View on medRxiv
Show abstract

BackgroundAdjuvant abemaciclib+endocrine therapy (ET) improves long-term outcomes in high-risk, hormone receptor-positive (HR+)/HER2-negative early breast cancer (eBC). However, treatment is frequently complicated by diarrhea, affecting adherence and quality of life (QoL). Increasing evidence suggests that abemaciclib-induced gastrointestinal toxicity may involve gut microbiota alterations. We conducted a prospective case-control pilot study evaluating the efficacy of MBR-01, a standardized preb...

Predicted journal destinations

1
Cancers
57 training papers
Top 2% 11.7%
2
PLOS ONE
1737 training papers
Top 53% 11.7%
3
Scientific Reports
701 training papers
Top 38% 6.4%
4
Frontiers in Oncology
34 training papers
Top 2% 6.4%
5
Nature Communications
483 training papers
Top 16% 6.4%
6
eLife
262 training papers
Top 5% 5.9%
7
Clinical Cancer Research
22 training papers
Top 2% 5.0%
8
BMC Cancer
21 training papers
Top 0.5% 4.1%
9
BMJ Open
553 training papers
Top 39% 3.8%
10
British Journal of Cancer
22 training papers
Top 2% 3.8%
11
Cancer Medicine
17 training papers
Top 1% 3.8%
12
Journal of Clinical Medicine
77 training papers
Top 9% 1.9%
13
Frontiers in Immunology
140 training papers
Top 8% 1.5%
14
Gut Microbes
15 training papers
Top 1% 1.3%
15
JAMA Network Open
125 training papers
Top 17% 1.3%
16
iScience
74 training papers
Top 8% 1.1%
17
PeerJ
46 training papers
Top 6% 0.9%
18
Gut
17 training papers
Top 2% 0.7%
19
Frontiers in Medicine
99 training papers
Top 24% 0.7%
20
Diagnostics
36 training papers
Top 6% 0.7%
21
Communications Medicine
63 training papers
Top 7% 0.7%
22
International Journal of Molecular Sciences
39 training papers
Top 7% 0.7%
23
Proceedings of the National Academy of Sciences
100 training papers
Top 20% 0.7%
24
Cell Reports
25 training papers
Top 3% 0.7%